Multiple media channels, both national and international, have echoed a study published by Robert E. Coleman (University of Sheffield) in the Lancet Oncology and which involved Roger Gomis (IRB Barcelona). The work allows early detection of patients who could benefit from zoledronic acid and those who should avoid it. Such early detection would thus accelerate the administration of the first preventive treatment for metastasis.
Link to JANO
Link to La Vanguardia
Link to EFE Futuro
Link to BioTech
Link to Medindia
Link to Medical Xpress
Link to ecancer